⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for modified t cells

Every month we try and update this database with for modified t cells cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen MesothelinNCT02414269
Malignant Pleur...
Mesothelioma
Metastases
Lung Cancer
Breast Cancer
iCasp9M28z T ce...
cyclophosphamid...
pembrolizumab
18 Years - Memorial Sloan Kettering Cancer Center
Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory OsteosarcomaNCT03721068
Neuroblastoma
Osteosarcoma
iC9.GD2.CAR.IL-...
Cyclophosphamid...
Fludarabine
18 Months - UNC Lineberger Comprehensive Cancer Center
T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic LeukemiaNCT01860937
Relapsed B-Cell...
leukapheresis o...
cyclophosphamid...
modified T cell...
- 26 YearsMemorial Sloan Kettering Cancer Center
Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen MesothelinNCT02414269
Malignant Pleur...
Mesothelioma
Metastases
Lung Cancer
Breast Cancer
iCasp9M28z T ce...
cyclophosphamid...
pembrolizumab
18 Years - Memorial Sloan Kettering Cancer Center
CD30 CAR for CD30+ NSGCTNCT05634785
Germ Cell Tumor
Nonseminomatous...
ATLCAR.CD30 Cel...
Cyclophosphamid
Fludarabine
18 Years - UNC Lineberger Comprehensive Cancer Center
Consolidation Therapy With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 in Patients With Chronic Lymphocytic Leukemia Following Upfront Chemotherapy With Pentostatin, Cyclophosphamide and RituximabNCT01416974
Leukemia
cyclophosphamid...
modified T cell...
18 Years - Memorial Sloan Kettering Cancer Center
Consolidation Therapy With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 in Patients With Chronic Lymphocytic Leukemia Following Upfront Chemotherapy With Pentostatin, Cyclophosphamide and RituximabNCT01416974
Leukemia
cyclophosphamid...
modified T cell...
18 Years - Memorial Sloan Kettering Cancer Center
Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory OsteosarcomaNCT03721068
Neuroblastoma
Osteosarcoma
iC9.GD2.CAR.IL-...
Cyclophosphamid...
Fludarabine
18 Months - UNC Lineberger Comprehensive Cancer Center
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: